Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)
Insiders here have filed 4 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$98.6M
- Net margin
- —
Little or no net debt.
- Total debt
- $467K
- Cash
- $6.8M
- Debt / equity
- 0.01
Comfortably covers what is due within a year.
- Current assets
- $93.1M
- Current liabilities
- $11.8M
- Current ratio
- 7.90
Consumes cash and must keep raising it.
- Operating cash flow
- -$73.9M
- Free cash flow
- -$73.9M
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 113.6M
- Share growth (1y)
- 47.3%
- Cash runway
- 1 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
ELDN Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A Expense | 4.64 M | 3.98 M | 3.99 M | 4.10 M | 4.46 M | 4.43 M |
| R&D Expense | 18.23 M | 17.20 M | 17.49 M | 14.97 M | 20.28 M | 13.53 M |
| Operating Expenses | 22.87 M | 21.18 M | 21.48 M | 19.07 M | 24.73 M | 17.96 M |
| Operating Income | -22.87 M | -21.18 M | -21.48 M | -19.07 M | -24.73 M | -17.96 M |
| Pretax Income | -31.63 M | -39.02 M | -10.41 M | -17.46 M | -11.22 M | -6.50 M |
| Tax Provision | 0.00 | 0.00 | 35.00 K | 0.00 | 0.00 | 0.00 |
| Net Income | -31.63 M | -39.02 M | -10.45 M | -17.46 M | -11.22 M | -6.50 M |
| EPS (Basic) | -0.27 | -0.35 | -0.14 | -0.23 | -0.15 | -0.08 |
| EPS (Diluted) | -0.27 | -0.35 | -0.14 | -0.23 | -0.15 | -0.08 |
| Shares Outstanding | 113.63 M | 112.42 M | 75.43 M | 77.16 M | 77.16 M | 77.13 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.